{"name":"Warner Chilcott","slug":"warner-chilcott","ticker":"","exchange":"","domain":"","description":"Warner Chilcott was a company in the pharmaceutical industry based in Rockaway, New Jersey. It was primarily focused on women's healthcare and dermatology. On October 1, 2013, the company was acquired by Actavis.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2541000000,"revenueGrowth":315.2,"grossMargin":0,"rdSpend":103000000,"netIncome":403000000,"cash":4218000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"1981-01-01","label":"Oxtriphylline first approved","drug":"Oxtriphylline","drugSlug":"choline-theophyllinate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Lialda","genericName":"Lialda","slug":"lialda","indication":"Other","status":"marketed"},{"name":"Oxtriphylline","genericName":"choline theophyllinate","slug":"choline-theophyllinate","indication":"Other","status":"marketed"},{"name":"Udenafil 100 mg","genericName":"Udenafil 100 mg","slug":"udenafil-100-mg","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Lialda","genericName":"Lialda","slug":"lialda","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oxtriphylline","genericName":"choline theophyllinate","slug":"choline-theophyllinate","phase":"marketed","mechanism":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","indications":[],"catalyst":""},{"name":"Udenafil 100 mg","genericName":"Udenafil 100 mg","slug":"udenafil-100-mg","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTHpMdW1VZ1dudVNfdzB2NnNoaFJUV1JUemhEbjAta2VuQ1pSMnFPbWluem1tUzNfS01YZUtjX2JXUGhMeUhvSFBmTUJfWFgwMzJnVDhyNEtfYnZkSGFkVGQtSGwtU1Z6NGVZVEgyd1hKRzZsVU9jTVZydGxKYlBUZkRhRnpKZC0wZ1dncTNFQ1k5cElSWm1rLWhn?oc=5","date":"2021-07-17","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Actavis makes definitive agreement with Warner Chilcott - Generics and Biosimilars Initiative","headline":"Actavis makes definitive agreement with Warner Chilcott","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQOTNLUVBPYU0tSkF2alFuS2dVck5RVHlQMDV2Tkw4NExxcUZIWlJveERRZG5QZmdLS1NxMFVlaE9XNWRYMU9lSUFUUXM3dnpfTVNhdmZOMUJvMmpMUE1qWE9BV0dhT2h2Y1pHRnBRWG1VMUw4cDR3SjU3Zm5qWXAtcTMxTWxTVWdEX19DS2pRaw?oc=5","date":"2019-10-11","type":"pipeline","source":"Petrie-Flom Center","summary":"Stopping the Pharmaceutical “Product Hop” - Petrie-Flom Center","headline":"Stopping the Pharmaceutical “Product Hop” - Petrie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZnlnVE4xS1N5SFo3WkFKdHJqWmFJaElzTUpJVTJCbnVKR3ZZZmF3VDRFVnNaQ3UtWXR2V3lIRHdVN01fTnRYMEZpbXVaWkllQzUteEYzejd1T1ZWMFUtNjB6eVRTckoyVUk0TlZJb09RZW5LMlAtakVmNkFrNjhJUU1jcGJFTGRqdkhqRGR6b25KVDJPdER4LW45UkhOX3JHMkhhU3ZYdWw?oc=5","date":"2016-07-12","type":"pipeline","source":"Fierce Healthcare","summary":"Editor’s Corner: Why are we still letting pharma pay physicians? - Fierce Healthcare","headline":"Editor’s Corner: Why are we still letting pharma pay physicians?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPeGpQYUNxWlY3SkQ5NlRkOWdEbWVtZDV0c09RT2hMUURzbnFCdDI0bTJZV1lFQ0ZYVFB0a2RfTXRORVRwNy1JWGFmc1RQaXFuUXJSejhoV2cxVm5RZG1PZE1CNmlaSVVSRkY2dGRUQ19yakZJbDU5SnhUR1dwRHh5VUdHMVJnVVpFVHVOSGlTTFBDT3M1bHoyYzZnY0NLb2xKMlZfN1J5ME5UalZnWVdYMno2Y2EtVmFuOV80dUkzTlp3eC1Qdm9Rai1KVGRSZjdZang4anFoRkNYSkE0ZzRpdWZn?oc=5","date":"2015-04-22","type":"pipeline","source":"Buchanan Ingersoll & Rooney","summary":"District Court Dismisses All Claims Against Warner Chilcott and Mayne Pharmaceuticals in “Product Hopping” Case - Buchanan Ingersoll & Rooney","headline":"District Court Dismisses All Claims Against Warner Chilcott and Mayne Pharmaceuticals in “Product Hopping” Case - Buchan","sentiment":"neutral"},{"date":"2013-10-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQQi1RQjhPWWVtNHNEVE4yNTNkOENPcXJYSmRpWTh5SXZHTVBpRk4yZEZPNFRZa3ZBRDNzMGxaTlFWaEM1YVdPbFYwLXl2b2dldHBheGJhbU84S0dkRkdSakktTjFRTTk3NTRpT0hacTVyVFZBb0VJWmVxOFdNMll0dGQteWh4V0dYQXk2ZjhKdko5b2tIRFoxaWsycVYwUHlfOHU4?oc=5","date":"2013-10-01","type":"pipeline","source":"PR Newswire","summary":"Actavis Completes Warner Chilcott Acquisition - PR Newswire","headline":"Actavis Completes Warner Chilcott Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNMXZpOHI2aDBWWmprMkllU3h6cm5iUUlET0RPWHNQRm1nR2hhdTlIVVV4M1B3X2d1bkY1T0hyUlpQUGtsc2JFcEtUekJLbzEwamVqVUViZG1ubUU2U2NpQTJXd1MzLXgwczdfNmlIdlRhTGluRDFxbE1RbjJreXI2ZmRvWi12N1lxdlVPRE84a3dwZU9oY2VRQjJQcG5oRXdPRm5Qb2I4a2lTWU1WeEFuVjdQbTJYenlGRFg1dnRDZUlRX2FoMnN1eWpFWlJGdWRJMFdLSWljUERxUFhZeU5GWDBsMkZfdmFvV3V2UnJCSjhoRlBwalRBRF9Icw?oc=5","date":"2013-05-20","type":"earnings","source":"PR Newswire","summary":"Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company - PR Newswire","headline":"Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOcF95ZG9KM05YRVBFZ1B2eFE0b1BOaUNyYXFZa0JkUTk4d0ZKS1dZVFY5RW5Td2IxSXd6REVZa0xVWWtreV9PRHBoWmowWFBwRXpra19lbWw5QXotOW1EZDA3NURsS2o2REwyUENwaXhnNTdmQmZCNThLS2lUTkU3MVgzUjl0bmJrcU1QNHFOX0hvTTg2OFNJ0gGcAUFVX3lxTE5pTkpSaTVJd3JQU0k3LXdHb2FmSmJXb1dKZzlpanBKd2tkS2ZCczZaZzAwcHAtdl9GYTYwWHNjS1Fmdk1xelltMG93VGZDcW9Vd2QteGxtU1kyZGNKVWZSNkFOUUlUWGdzX2taM1U5VkpuRlhSZkdCbHlqWVZ6RWZFc0JzUlpkb2pfb2tDYnhLUmJJVl9jWUhaVkp5Tg?oc=5","date":"2013-05-20","type":"deal","source":"CNBC","summary":"Actavis to Buy Warner Chilcott in $8.5 Billion Stock Deal - CNBC","headline":"Actavis to Buy Warner Chilcott in $8.5 Billion Stock Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQVGtTYU1tbjY4TklVLUc2Vkh1eWwtLU1RUTNXQk1mMVNBWGRjTmQ0dDZDb015Yy1XNXRObGo1OTNUaDFOWVBPb0NDWk5XVzI5SEFHT0hEcmpjSG1raTdkTS1vNkFCMkhadldkLTYzZFZnNWdFMTk5WXJFZThURnlWcg?oc=5","date":"2013-05-20","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Actavis Acquiring Warner Chilcott for $8.5B - Genetic Engineering and Biotechnology News","headline":"Actavis Acquiring Warner Chilcott for $8.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPUC10V0xsc1hETllvdUYtYTZDd0h3aVFQWFhmUmhpZEZMR3dJZTM5WG91X0F4R3F1RVRGVEFLdjJuS3dGN01ZM2QxRkxza0U0T1JwakU3Y1ZWWjI5NHl6cUlIRE01ZEQxSElqUUVMZGVYemZjRjlZRVRreVdZT2FfYUFLSHNlNzgxOEJkazEwc3VDbHRXZzRaQkR3?oc=5","date":"2013-05-20","type":"deal","source":"USA Today","summary":"Actavis buying Warner Chilcott in $8.5B deal - USA Today","headline":"Actavis buying Warner Chilcott in $8.5B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNRGRiUG5nTmFHRXgyV043OHZmSzRvZGxLT1g1allqRWItRUc3dzBXRlYyWlhUeFc5ck54amJpTXllMFVfRlFSZ3duWDI0Vzl6bHM2REhTNWZ6OGRKNk9GRjQ4N0syWDdBRUEweGdLRXM1WEQ3RS1FcE1XQWhCcjI5R0tjVl8?oc=5","date":"2013-05-13","type":"deal","source":"PMLiVE","summary":"Actavis in talks to buy Warner Chilcott - PMLiVE","headline":"Actavis in talks to buy Warner Chilcott","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNVWtBTWJudXhKRTFSenl6dUQtb1NCY1REb0ZXTE1fb0NXdGktdjNTZWt6TG5Na0l5anU0NzBha1dTZFJfbTJ3Mm9SMWt6SFlySDVBZkwtQ1ROWGlYWHM3TmtzWjc2M0l1M2hXYmlHSzlITFAwNEtHSHpoSEtqSzE2UG5mTGxhei1BVnZMSm9QZGNKdWtwMW40YXhVSnkyODNmdnc?oc=5","date":"2010-10-22","type":"regulatory","source":"Fierce Pharma","summary":"Warner Chilcott Announces FDA Approval of New Oral Contraceptive - Fierce Pharma","headline":"Warner Chilcott Announces FDA Approval of New Oral Contraceptive","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1VVnptaGJRck9mNEtqd2s0RlZGcE12RGxLeXAyQ0JBX2VQLUxsalh2N1RIWDZ0MXRaSzVMNXljVGtuM0tBSE1EeGtuMzd5WlR3UjdSYWJnc2tUelpDQzB3MUNQNHhSZUprWGRuVlhqbUY3bDBj?oc=5","date":"2009-08-31","type":"pipeline","source":"C&EN","summary":"P&G Sells Drug Unit To Warner Chilcott - C&EN","headline":"P&G Sells Drug Unit To Warner Chilcott - C&EN","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":2541000000,"revenuePeriod":"2012-12-31","revenueHistory":[{"value":2541000000,"period":"2012-12-31"},{"value":612000000,"period":"2012-12-31"},{"value":606000000,"period":"2012-09-30"},{"value":638000000,"period":"2012-06-30"},{"value":685000000,"period":"2012-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":103000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":403000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":4218000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}